Results 121 to 130 of about 23,143 (200)
British Journal of Pharmacology, Volume 183, Issue 19, Page 5832-5853, October 2026.Serotonin differentially modulates layer 5 mPFC microcircuits through cell type‐specific pre‐ and postsynaptic receptor pathways. Presynaptic 5‐HT1BRs suppress glutamate and GABA release, whereas presynaptic and postsynaptic 5‐HT3ARs enhance fast‐spiking interneuron activity, whilst distinct pyramidal neuron subtypes exhibit divergent 5‐HT1AR‐ and 5 ...
Ramya Rama +4 more
wiley +1 more source
, 2015 Yubing Zhu,1 Qian Zhang,1 Jianjun Zou,2 Meng Wan,1 Zheng Zhao,1 Junrong Zhu1 1Department of Pharmacy, 2Laboratory of Clinical Pharmacology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China ...
Zhu YB +5 more
core
Clinical and Translational Science, Volume 19, Issue 10, October 2026.Real‐world prescription data from 6230 adolescents and adults living with sickle cell disease (SCD) were combined with a drug–drug interaction (DDI) database to characterize the population‐level DDI risk. The findings support a DDI risk assessment for development of novel SCD therapies and during clinical management of SCD.ABSTRACTSickle cell disease ...
Rune Aabjerg Nørgaard +4 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju +6 more
wiley +1 more source
Ondansetron prevents postoperative nausea and vomiting in women outpatients.
, 1994 Three doses of intravenous (i.v.) ondansetron, 1 mg, 4 mg, and 8 mg, were compared to placebo for their antiemetic effect and safety. The drugs or placebo were administered in a double-blind manner, prophylactically to 589 women undergoing elective ...
Kataria, B +9 more
core +1 more source
Ondansetron does not reduce the shivering threshold in healthy volunteers [PDF]
, 2017 Background. Ondansetron, a serotonin-3 receptor antagonist, reduces postoperative shivering. Drugs that reduce shivering usually impair central thermoregulatory control, and may thus be useful for preventing shivering during induction of therapeutic ...
Lauber, R. +7 more
core
Hemodialysis International, Volume 30, Issue 4, Page 679-688, October 2026.ABSTRACT Introduction End stage kidney disease (ESKD) is associated with a high prevalence of depression and anxiety, arising from both biological factors and the psychosocial burden of chronic dialysis care. Approximately 25%–30% of dialysis patients experience clinically significant depressive symptoms when assessed by structured clinical interview ...
Kunal Malhotra +2 more
wiley +1 more source
, 1996 The purpose of this study was to investigate the efficacy and safety of oral ondansetron, given alone or in combination with dexamethasone in the control of cisplatin-induced delayed emesis.I. Olver, W. Paska, A. Depierre, J.-F. Seitz, D. J.
Olver, Ian N. +8 more
core
Inhibitory Effect of Ondansetron on Glycine Response of Dissociated Rat Hippocampal Neurons 1
, 2020 We examined the effect of ondansetron, an antagonist of type 3 serotonin receptors, on the whole cell response of freshly isolated hippocampal CA1 pyramidal neurons of neonatal and "mature" rats to glycine using the gramicidin perforated patch ...
V K Z +5 more
core
Internal Medicine Journal, Volume 56, Issue 10, Page 1765-1774, October 2026.Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid +4 more
wiley +1 more source